Squarepoint’s Charles River Laboratories CRL Stock Holding History

Squarepoint’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,000	Closed	-$939K	–	4360
2025 Q3	$939K	Sell	6,000 -25,000	-81%	-$3.97M	﹤0.01%	2746
2025 Q2	$4.7M	Buy	+31,000	New	+$4.13M	﹤0.01%	1505
2025 Q1	–	Sell	-2,300	Closed	-$425K	–	4713
2024 Q4	$425K	Sell	2,300 -600	-21%	-$116K	﹤0.01%	3877
2024 Q3	$571K	Sell	2,900 -2,200	-43%	-$457K	﹤0.01%	2992
2024 Q2	$1.05M	Sell	5,100 -100	-2%	-$22.7K	﹤0.01%	2517
2024 Q1	$1.41M	Sell	5,200 -6,100	-54%	-$1.46M	﹤0.01%	2334
2023 Q4	$2.67M	Buy	+11,300	New	+$2.22M	0.01%	1810

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Squarepoint's CRL Position: Q1 2026 in Review

Squarepoint reduced its Charles River Laboratories (CRL) stake by 0.3% in Q1 2026, selling an estimated $742 and leaving 1,308 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3897.

Squarepoint first reported a position in CRL in Q2 2015 and has held it in 35 quarters since. The position peaked at $17.6M in Q1 2022. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Squarepoint held 1,308 shares of Charles River Laboratories worth $226K as of Q1 2026.
Squarepoint sold 4 Charles River Laboratories shares in Q1 2026, an estimated $742.
Charles River Laboratories made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3897 holding.
Squarepoint first reported a position in Charles River Laboratories in Q2 2015 and has held it in 35 quarters since.
Squarepoint's Charles River Laboratories position peaked at $17.6M in Q1 2022.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.